Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2008
Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Ambulatory management of low-risk febrile neutropenia in adult oncological patients. Systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Pooled it
- Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event.The Cochrane database of systematic reviews · 2019Pooled it
- Clinical and cost-effectiveness, safety and acceptability ofBMJ open · 2017Pooled it
- Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients.The Cochrane database of systematic reviews · 2013Pooled it
- Usefulness analysis of the 2018 ASCO/IDSA guideline for outpatient management of fever and neutropenia in adults treated for malignancy.Scientific reports · 2021Article
- Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen.Journal of clinical and experimental hematopathology : JCEH · 2020Article
- Is current initial empirical antibiotherapy appropriate to treat bloodstream infections in short-duration chemo-induced febrile neutropenia?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Observational
- A cohort study on protocol-based nurse-led out-patient management of post-chemotherapy low-risk febrile neutropenia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Article
- Outpatient management without initial assessment for febrile patients undergoing adjuvant chemotherapy for breast cancer.Molecular and clinical oncology · 2016Article
- Independent factors for prediction of poor outcomes in patients with febrile neutropenia.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- Gender analysis of moxifloxacin clinical trials.Journal of women's health (2002) · 2014Review
- The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Review
- Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012Article
- Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2011Article
- Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients.British journal of cancer · 2011Article
- Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2010Article
- Predicting the complicated neutropenic fever in the emergency department.Emergency medicine journal : EMJ · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
goals of workPatients with low-risk neutropenic fever as defined by the Multinational Association of Supportive Care in Cancer (MASCC) score might benefit from ambulatory treatment. Optimal management remains to be clearly defined, and new oral antibiotics need to be evaluated in this setting. MATERIALS AND
methodsCancer patients with febrile neutropenia and a favorable MASCC score were randomized between oral moxifloxacin and intravenous ceftriaxone. All were fit for early hospital discharge. The global success rate was related to the efficacy of monotherapy, as well as to the success of ambulatory monitoring. MAIN
resultsThe trial was closed prematurely because of low accrual. Ninety-six patients were included (47 in the ceftriaxone arm and 49 in the moxifloxacin arm). A total of 65% were women, 30.2% had lymphoma, 34.4% had metastatic, and 35.4% had non-metastatic solid tumors. The success rates of home antibiotics were 73.9% and 79.2% for ceftriaxone and moxifloxacin, respectively. Seven patients were not discharged, and 14 required re-hospitalization. There were 17% of microbiologically documented infections that were, in most cases, susceptible to oral monotherapy.
conclusionsThese results suggest that MASCC is a valid and useful tool to select patients for ambulatory treatments and that oral moxifloxacin monotherapy is safe and effective for the outpatient treatment of cancer patients with low-risk neutropenic fever.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.